EGRX - イ―グル・ファ―マシュ―ティカルズ (Eagle Pharmaceuticals Inc.)

EGRXのニュース

   Eagle Pharmaceuticals (NASDAQ:EGRX) Releases Earnings Results, Beats Expectations By $2.38 EPS  2021/03/04 00:20:51 Transcript Daily
Eagle Pharmaceuticals (NASDAQ:EGRX) issued its quarterly earnings results on Monday. The specialty pharmaceutical company reported $0.96 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.42) by $2.38, MarketWatch Earnings reports. Eagle Pharmaceuticals had a return on equity of 8.50% and a net margin of 2.65%. EGRX traded down $0.08 during […]
   Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Results and Provides Pipeline Review  2021/03/02 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and twelve months ended December 31, 2020, and reviewed key pipeline programs. Business and Recent Highlights: Posted strong year-over-year adjusted non-GAAP earnings growth of 36%; Received a complete response letter (“CRL”) from U.S. Food and Drug Administration (“FDA”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Ea
   Eagle Pharmaceuticals (EGRX) Set to Announce Earnings on Tuesday  2021/02/28 07:22:41 Transcript Daily
Eagle Pharmaceuticals (NASDAQ:EGRX) is set to post its quarterly earnings results before the market opens on Tuesday, March 2nd. Analysts expect Eagle Pharmaceuticals to post earnings of ($1.42) per share for the quarter. Individual that are interested in participating in the company’s earnings conference call can do so using this link. Shares of NASDAQ:EGRX opened […]
   Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2020 Financial Results and Pipeline Review on March 2, 2021  2021/02/22 21:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (“Eagle” or the “Company”) (Nasdaq: EGRX) today announced that the Company will release its 2020 fourth quarter and full year financial results on Tuesday, March 2, 2021, before the market opens. Scott Tarriff, Chief Executive Officer, Brian Cahill, Chief Financial Officer, senior members of Eagle’s executive leadership team, and other distinguished external speakers will host a 90- minute conference call as follows: Date Tuesda
   Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial  2021/02/02 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for its Abbreviated New Drug Application (“ANDA”) for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days. Importantly, Eagle has completed an extensive amount of developmental work and continu
   Eagle Pharmaceuticals Announces Update in Vasopressin Trial; Trial Date Postponed from January 11, 2021 to February 1, 2021 to Protect Against COVID-19 Concerns  2021/01/11 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that, on January 8, 2021, the United States District Court for the District of Delaware postponed the January 11, 2021 vasopressin trial between Eagle and Endo Par Innovation Company, LLC, et al. due, in part, to ensure the health and safety of the trial teams in light of a COVID-19 concern. The trial is now scheduled to begin remotely starting February 1, 2021 and is exp
   Eagle Pharmaceuticals to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/04 21:30:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that Scott Tarriff, Chief Executive Officer, and Brian Cahill, Chief Financial Officer, will present at the 39th Annual J.P. Morgan Healthcare Conference as follows: Date: Wednesday, January 13, 2021 Time: 4:30 p.m. Eastern Standard Time Webcast: https://jpmorgan.metameetings.net/events/healthcare21/sessions/35699-eagle-pharmaceuticals/webcast?gpu_only=true&kiosk=true
   Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing  2020/11/23 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company’s website at www.eagleus.com, under the Inves
   Eagle Pharmaceuticals Inc. (EGRX) Q3 2020 Earnings Call Transcript  2020/11/02 17:30:04 AlphaStreet
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Q3 2020 Earnings Call dated Nov. 02, 2020 Corporate Participants: Lisa M. Wilson — Investor Relations – In-Site Communications, Inc. Scott Tarriff — Founder, Chief Executive Officer and Director […]
   Earnings Scheduled For November 2, 2020  2020/11/02 12:55:36 Benzinga
Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.
   Eagle Pharmaceuticals’ Presentation at Piper Sandler 32nd Annual Virtual Healthcare Conference Available for Viewing  2020/11/23 11:50:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that the Company’s pre-recorded presentation at the Piper Sandler 32nd Annual Virtual Healthcare Conference is now available for viewing via the link below: https://pipersandler.zoom.us/rec/play/0TlXfXVGZ3QG7IgEE4PyzFEfiG8HyD57XqSaO9Uq1Rsb_J29jmyS2ZvqWskPC1MJPA_AP6kFUMjJQfFd.vyuNfKmJI0FvhIOg It is also available on the Company’s website at www.eagleus.com, under the Inves
   Eagle Pharmaceuticals Inc. (EGRX) Q3 2020 Earnings Call Transcript  2020/11/02 17:30:04 AlphaStreet
Eagle Pharmaceuticals Inc. (NASDAQ: EGRX) Q3 2020 Earnings Call dated Nov. 02, 2020 Corporate Participants: Lisa M. Wilson — Investor Relations – In-Site Communications, Inc. Scott Tarriff — Founder, Chief Executive Officer and Director […]
   Earnings Scheduled For November 2, 2020  2020/11/02 12:55:36 Benzinga
Companies Reporting Before The Bell • Itron (NASDAQ: ITRI ) is likely to report quarterly earnings at $0.25 per share on revenue of $540.01 million. • AMC Networks (NASDAQ: AMCX ) is projected to report quarterly earnings at $1.28 per share on revenue of $606.04 million. • BWX Technologies (NYSE: BWXT ) is likely to report quarterly earnings at $0.68 per share on revenue of $499.24 million. • Clorox (NYSE: CLX ) is projected to report quarterly earnings at $2.32 per share on revenue of $1.75 billion. • Camping World Holdings (NYSE: CWH ) is estimated to report quarterly earnings at $0.96 per share on revenue of $1.51 billion. • Eagle Pharmaceuticals (NASDAQ: EGRX ) is likely to report quarterly earnings at $0.28 per share on revenue of $47.02 million. • Exterran (NYSE: EXTN ) is likely to report quarterly loss at $0.48 per share on revenue of $194.32 million. • FirstEnergy (NYSE: FE ) is likely to report quarterly earnings at $0.76 per share on revenue of $2.94 billion. • MGM Growth Properties (NYSE: MGP ) is expected to report quarterly earnings at $0.
   Eagle Pharmaceuticals Reports Third Quarter 2020 Results  2020/11/02 11:47:00 Business Wire
WOODCLIFF LAKE, N.J.--(BUSINESS WIRE)--Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced financial results for the three and nine months ended September 30, 2020. Business and Recent Highlights: Received formal notification from FDA granting Priority Review for the Company’s abbreviated new drug application (“ANDA”) filed for vasopressin. A trial date of January 11, 2021 has been set; Added four experienced pharmaceutical industry executives to clinical, form
   The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings  2020/11/01 14:40:39 Benzinga
Biotech stocks continued to sway to the tunes of the broader market in the week ended Oct. 30, which succumbed to geopolitical and macroeconomic concerns. Several big-name pharma companies, including Merck & Co. Inc. (NYSE: MRK ) and Pfizer Inc. (NYSE: PFE ), reported earnings during the week. The earnings news flow was broadly mixed. Catabasis Pharmaceuticals Inc (NASDAQ: CATB ) was among the biggest decliners, as it halted a late-stage trial of its Duchenne muscular dystrophy drug. On the other hand, Scholar Rock Holding Corp. (NASDAQ: SRRK ) was up about over 175% during the week, reacting to positive mid-stage results for spinal muscular atrophy drug. On the COVID-19 front, Regeneron Pharmaceuticals Inc. said it is (NASDAQ: REGN ) halting the Phase 3 trial of its antibody cocktail in patients with severe COVID-19, citing safety issue. Kala Pharmaceuticals Inc. (NASDAQ: KALA ) announced FDA approval for its dry eye disease drug, while Spectrum Pharmaceuticals Inc. (NASDAQ: SPPI ) communicated a delay in the decision for its treatment option for chemotherapy-induced neutropenia, as the FDA could not inspect a plant in South Korea due to COVID-19.

calendar